LDS/Medical Tests/Cancer Antigen (CA) 27- 29

Cancer Antigen (CA) 27- 29

Breast carcinoma is a common malignancy in women, and the incidence increases after the age of 20 years. An initial sign associated with breast cancer is often a small, painless nodule located in the breast tissue. Many breast cancers are found by doing yearly mammography to detect non-palpable lesions and areas of suspicious calcifications. A biopsy confirms a malignant condition and the course of treatment can be monitored with blood tests. The CA 27–29 test is useful for monitoring patients with advanced stages of breast cancer. In early stages this test has low sensitivity and specificity. Because of this The American Society of Clinical Oncology recommends using this test only during metastatic conditions.

In most cases the CA 27-29 test does not provide sufficient information to consider treatment options. Major factors contributing to carcinoma of the breast are familial occurrence and hormonal level exposure, specifically estrogen. Other factors to the disease include fibrocystic disease with atypical hyperplasia, prior carcinoma of the uterus, and exposure to radiation of the chest. CA 27-29 is not specific for breast cancer and it may be elevated in cancers of the colon, stomach, kidney, lung, ovary, pancreas, uterus, and liver. First trimester pregnancy, endometriosis, ovarian cysts, benign breast disease, kidney disease, and liver disease are non-cancerous conditions that may give an elevated CA 27-29.

  • Diagnostic in patient with metastatic adenocarcinoma of the breast
  • Disease management and therapy monitoring
  • Monitoring for the recurrence of breast carcinoma in patients with stage II and III

Increased in:

  • Breast carcinoma
  • Carcinoma of the colon
  • Carcinoma of the stomach
  • Carcinoma of the kidney
  • Lung cancer
  • Ovarian cancer
  • Pancreatic cancer
  • Liver cancer
  • First trimester pregnancy
  • Endometriosis
  • Ovarian cysts
  • Benign breast disease
  • Kidney disease
  • Liver disease

0-35 U/mL

 

Chemiluminescent, Immunoassay, ELISA

Serum (SST) or Plasma.

Stability

  • Ambient: 8 hours
  • Refrigerated: 1 week
  • Frozen: 1 year
Breast biopsy or lymph node fine needle aspiration, BRCA1, BRCA2, Beta-HCG, CA 15-3, CEA.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Methods Mol Biol. 2009;472:307-21. [PMID: 19107439]
  • Clin Chem. 2006 Mar;52(3):345-51. [PMID: 16410341]
  • Int J Biol Markers. 1999 Jan-Mar;14(1):36-9. [PMID: 10367248]
  • Biochemistry. 2003 Dec 9;42(48):14293-305. [PMID: 14640698]
  • Louise M. Immunology & Serology in Laboratory Medicine. St. Louis, MO: Mosby Elsevier Health Science (1996).